Loading clinical trials...
Loading clinical trials...
A Single Arm, Phase II Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Pretreated With Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitors
Conditions
Interventions
Atezolizumab
Bevacizumab
Locations
10
China
Beijing Cancer Hospital
Beijing, China
Beijing Hospital; Internal Medicine-Oncology
Beijing, China
Beijing Chest Hospital; Oncology Department
Beijing, China
West China Hospital, Sichuan University
Chengdu, China
Sun Yet-sen University Cancer Center
Guangzhou, China
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department
Hangzhou, China
Start Date
September 9, 2020
Primary Completion Date
January 19, 2022
Completion Date
February 10, 2023
Last Updated
May 21, 2024
NCT06667908
NCT04165798
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions